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Abstract. Resistant malaria parasites are frequently found in mixed infections with drug-sensitive parasites. Particularly
early in the evolutionary process, the frequency of these resistant mutants can be extremely low and below the level of
molecular detection. We tested whether the rarity of resistance in infections impacted the health outcomes of treatment
failure and the potential for onward transmission of resistance. Mixed infections of different ratios of resistant and
susceptible Plasmodium chabaudi parasites were inoculated in laboratory mice and dynamics tracked during the course
of infection using highly sensitive genotype-specific quantitative polymerase chain reaction (qPCR). Frequencies of
resistant parasites ranged from 10% to 0.003% at the onset of treatment. We found that the rarer the resistant parasites
were, the lower the likelihood of their onward transmission, but the worse the treatment failure was in terms of parasite
numbers and disease severity. Strikingly, drug resistant parasites had the biggest impact on health outcomes when they
were too rare to be detected by any molecular methods currently available for field samples. Indeed, in the field, these
treatment failures would not even have been attributed to resistance.
INTRODUCTION
Drug-resistant malaria parasites are a major threat to public
health.1–3 Detecting resistant parasites is important for moni-
toring and surveillance and to determine the health burden of
resistance.1 Resistant parasites frequently occur in infections
with sensitive parasites,4–6 a discovery first made with iso-
zymes and then early polymerase chain reaction (PCR)
methods.7 In recent years, more sensitive molecular marker
detection assays have been developed such as ligase detection
reaction fluorescent microspheres,5,8 high-resolution melting
assays,6,9 and ultra-deep sequencing.10 These newer methods
have reduced genotype detection thresholds from the frequen-
cies of 10% to 20% achievable with traditional restriction
fragment length polymorphism (RFLP) assays11,12 down to
1%. Ultra-deep sequencing has the theoretical potential to
go to even lower, though so far as we are aware, this has yet
to be achieved with field samples.
What role might resistant parasites play in determining
health outcomes and the onward transmission of resistance if
they are at frequencies of much less than 1%? Studying the
importance of undetectable parasites is clearly a challenge.
Here we investigate experimentally the impact of very rare
resistant parasites on treatment failure, disease severity, and
transmission using the rodent malaria model Plasmodium
chabaudi. In an experimental setting, frequencies as low as
0.0001% can be measured because the genotypes of all para-
sites in an infection are known and so specific primers can
be designed to follow each of them by quantitative PCR
(qPCR). We asked whether the frequency of resistant parasites
at the time of treatment affected 1) posttreatment parasite
dynamics, 2) disease severity caused by treatment failure,
and 3) onward transmission of resistance. We were also able
to study treatment failure that current technologies would not
attribute to resistance.
MATERIAL AND METHODS
Parasites and hosts. Two genetically distinct clones were
used: drug sensitive clone AJ5p (hereafter referred to as clone S)
and drug resistant clone AS6p(pyr-1A) (hereafter referred to as
clone R). Both clones were isolated from thicket rats, and
subsequently cloned.13 Clone R was made resistant by a
single high-dose exposure to pyrimethamine.14 Hosts were
8- to 15-week-old female C57Bl/6 laboratory mice (Charles
River Laboratories, Wilmington, MA). To test for background
variation in mouse health, a group of 10 sham-infected mice
was monitored contemporaneously. All mice were kept on a
12:12 light:dark cycle, fed Laboratory Rodent Diet 5001
(LabDiet, PMI Nutrition International, Brentwood, MO)
and received 0.05% para-aminobenzoic acid (PABA)–-
supplemented drinking water to enhance parasite growth.15
Experimental design, infections, and drug treatment. The
experiment consisted of mixed infections of clones R and S
(Table 1). The inoculum of clone R consisted of 106, 105, 103,
or 101 parasites and the inoculum of clone S was kept constant
at 106 parasites per mouse. Control mice were sham injected
with uninfected blood. Each treatment group consisted of five
mice, except for the group with an inoculum of 101 resistant
parasites, which consisted of 10 mice to allow for the possibil-
ity that some mice failed to become infected because of sto-
chastic loss due to the low inoculum size, which in the end did
not occur. Drug treatment started on day 6 postinfection (PI),
which is when pronounced anemia and weight loss begin to
show,16,17 and consisted of 8 mg/kg pyrimethamine dissolved
in dimethyl sulfoxide (DMSO), administrated by intraperito-
neal (i.p.) injection of 50 mL on 4 successive days. In previous
studies, clone R has been completely resistant to this regimen,
meaning that the drug did not affect parasitemia.4
Monitoring of infections.Weight and red blood cell (RBC)
density of the mice, together with asexual parasite density and
gametocyte density of both clones, were measured daily (day
3–21 PI) and three times a week thereafter (day 23–49 PI).
For each mouse (including uninfected control mice), 2 mL blood
was taken by tail snip at each sampling time for RBC density
measurements using flow cytometry (Beckman Coulter,
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High Wycombe, UK). A further 5 mL blood was taken for
DNA extraction, which was carried out on the ABI PrismÒ
6100 Nucleic Acid PrepStation (Applied Biosystems, Foster
City, CA) according to manufacturer’s instructions. A further
10 mL blood was taken and lysed immediately for RNA extrac-
tion, using the “RNA Blood-DNA” method on the ABI Prism
6100 Nucleic Acid PrepStation. Afterward, RNA was con-
versed to single-stranded complementary DNA (cDNA) using
the High-Capacity cDNAArchive Kit (Applied Biosystems).18
Both DNA and cDNA were stored at −80°C until quantifica-
tion. In addition, a thin blood smear was made of each mouse
on each sampling day.
To measure total parasite density (asexual parasites plus
gametocytes), qPCR was performed on DNA using clone-
specific assays.19 To measure gametocyte density, qPCR was
performed on cDNA, using the same clone-specific assays.19,20
Asexual parasite density was estimated by subtracting the
gametocyte density from the total parasite density.20 The PCR
reaction volume of 25 mL for all assays consisted of 7 mL DNA
or cDNA, 900 nM forward and reverse clone-specific primers,
250 nM TaqManÒ MGB probe (Applied Biosystems) and 1x
PerfeCTa™qPCRFastMix™ (QuantaBiosciences,Gaithersburg,
MD). All reactions were run on the ABI Prism 7500 Fast Sys-
tem (Applied Biosystems), using the assay: 95°C for 2 minutes,
followed by 40 cycles of 95°C for 3 seconds and 60°C for
30 seconds. Quantification was based on serial dilutions of
DNA and cDNA standards of known total parasite and game-
tocyte density, determined beforehand by careful microscopy.21
The study was carried out in strict accordance with the
recommendations in the guide for the Care and Use of Labo-
ratory Animals of the National Institutes of Health. The pro-
tocol was approved by the Animal Care and Use Committee
of the Pennsylvania State University (permit number: 35790).
Statistical analysis. Resistant asexual parasite densities and
gametocyte densities posttreatment (day 10–49 PI) were
summed to give an estimate of the total number of parasites
present after treatment. In addition, as a measure of disease
severity, maximum RBC loss and weight loss during relapse
were calculated as the difference between the baseline value
taken on the day before infection and the minimum reached
following regression after day 12 PI. Time to slide positivity
was estimated as an approximation of earliest relapse detec-
tion by thick smear microscopy under field circumstances. For
this, we used a cutoff value of 50 parasites/mL blood.22 Finally,
as a measure of transmission potential, the mean predicted
infectiousness was calculated for both genotypes from the end
of drug treatment (day 10 PI) onward using gametocyte den-
sities in the density–infectivity function for clone R as derived
from previous infection experiments.23 General linear models
were used throughout. Relapse size and relative abundance
at time of treatment were log transformed to meet normal-
ity assumptions. All statistical analyses were performed in
R 3.0.0.24
Three mice had to be excluded from the analysis. One
mouse died (103 R-inoculum), one failed for unknown reasons
to respond to drug pressure (103 R-inoculum), and one mouse
received an inoculum of several orders of magnitude lower
than intended, as judged by the pretreatment infection kinetics
(105 R-inoculum) (Table 1).
RESULTS
After inoculation, resistant parasites grew less rapidly than
susceptible parasites, which resulted in a reduction of relative
abundance from 50% resistant parasites in the highest abun-
dance group at time of inoculation to a mean of 9.7% resistant
parasites at time of treatment (day 6 PI). In the other groups,
frequencies of 9.1%, 0.1%, and 0.001% at inoculum became
averages of 1.2%, 0.01%, and 0.0003%, respectively, by the
time treatment was initiated (Figure 1).
Kinetics of treatment failure. As found previously,4,17,19
drug treatment rapidly reduced the susceptible parasite popu-
lation, allowing the expansion of the resistant parasite popu-
lation, even of the rare resistant parasites (Figure 1). This
relapse of resistant parasites was considerable in all treatment
groups, but counterintuitively, the lower the relative abun-
dance of resistance at time of treatment, the greater the post-
treatment relapse (F1,20 = 9.5, P = 0.006) (Figure 2A, 3A). The
time to peak relapse was longer when resistant parasites were
rare at time of treatment (mean of day 13.4, 14.0, 17.0, and
18.0 PI for infections in the very abundant, abundant, rare, and
very rare experimental groups, respectively) (Figure 2A).
Unexpectedly, the drug treatment dose was insufficient to
fully clear the susceptible parasite population. This led to a
substantial relapse of susceptible parasites in the groups that
started with rare or very rare resistant parasites. These relapses
occurred only when the density of the resistant parasites was
around 100 parasites/mL or lower at the end of treatment. The
lower the density of resistant parasites (very rare group),
the higher the relapse observed of the susceptible parasites
(Figures 1 and 3).
All mice, regardless of starting density of resistant mutants,
experienced treatment failure as defined by the World Health
Organization25 (parasites present at the end of treatment or
recrudescence). In 13 of the 22 infections, parasites were still
detectable by thick-smear microscopy the day after the end of
treatment. These 13 infections consisted of all nine infections
in the very abundant and abundant groups as well as two
infections in the rare treatment group and two in the very rare
group. The remaining nine infections manifested as recru-
descence: drug treatment reduced parasite densities below
microscopy detection the day after treatment ended, but par-
asites later recovered to densities above thick-smear detect-
ability. These nine relapsing infections all became slide
positive again 6–8 days after initiation of drug treatment, with
a mean of 7.3 days (Figure 1).
Host health. Uninfected control mice endured minor ane-
mia and weight loss, attributed to handling and sampling
stress, as well as drug and adjuvant side effects (Figure 4A
and B). Following treatment, mouse weight did not show any
significant deviations from steady growth and no differences
Table 1
Experimental setup
Resistant Susceptible n
Very abundant 106 106 5 (5)
Abundant 105 106 5 (4)
Rare 103 106 5 (3)
Very rare 101 106 10 (10)
Sham-injected control − − 5 (5)
Mice were simultaneously inoculated with given densities of resistant and susceptible
parasites. Control mice were sham injected with uninfected red blood cells. Drug treatment
was given on days 6–9 postinfection. The treatment group with very rare resistant parasites
consisted of 10 mice at the start of the experiment; all other treatment groups consisted of
five mice. Three mice had to be excluded from the analysis (see Methods); the number of
mice included in the analysis is given between brackets.
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were seen between treatment groups (Figure 4B and D).
In contrast, mice in all groups had a bout of anemia after
treatment as a consequence of parasite relapse, with the
exception of mice that started with a very high abundance of
resistant parasites (Figure 4A and C). These bouts of post-
treatment anemia were the greatest in the groups where resis-
tant parasites were rare or very rare (F3,18 = 3.7, P = 0.031).
Because the relapse parasite peak occurred later in these
groups, anemia peaks were also later (F3,18 = 25, P < 0.001)
(Figure 4E). Thus, treatment failure had the biggest impact on
host health when resistant parasites frequencies were < 0.01%
at the time of treatment.
Figure 1. Asexual parasite dynamics of resistant and susceptible parasites depicted separately for each individual mouse that received an
inoculum with very abundant, abundant, rare, or very rare resistant parasites (see column headings). Vertical grey area shows timing and duration
of treatment. Asterisk indicates a mouse that received a lower dose of resistant parasites than intended, the cross indicates a mouse that died
during the infection, and the diamond indicates a mouse that did not respond to treatment because of unknown reasons. These three mice were
excluded from the analysis (see Methods and Table 1). Horizontally shaded areas represent different levels of thick-smear microscopy detection
ability. In lightest shade is the generally assumed detection threshold under field circumstances (50–100 parasites/mL, this could be even higher).
Below that is the detection threshold under ideal laboratory circumstances (4–50 parasites/mL). At the bottom is the density that is considered to
be below microscopy detection level.22
Figure 2. Mean total asexual parasite dynamics (A) and gametocyte dynamics (B) following initiation of treatment. Infections were initiated
with either very abundant (106, blue lines); abundant (105, red lines); rare (103, yellow lines); and very rare (101, green lines) inoculations of resistant
parasites, contemporaneously with 106 susceptible parasites. Drug treatment was given on days 6–9 postinfection. Data are means (± standard error)
of the total density of up to 10 mice.
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Transmission stages. The dynamics of the transmission
stages of the relapsing parasites followed the dynamics of the
asexual parasites (Figures 2B and 5). Yet, in contrast to asexual
parasite densities, the more common resistant parasites were on
the first day of treatment, the more resistant gametocytes were
detected in the period after treatment (F1,20 = 4.5, P = 0.038)
(Figure 3C). To estimate the transmission potential of the
relapses, we used an empirically derived gametocyte density-
infectivity function.23 Resistant parasites had the highest poten-
tial to transmit when they started the infection at a higher
density (F3,18 = 7.9, P = 0.001) (Figure 6A). The transmission
potential of the susceptible parasites during relapse was negli-
gible (Figure 6B).
DISCUSSION
Malaria treatment failure due to drug resistance is a signifi-
cant medical and public health challenge. Using a rodent
model, we created infections in which resistant parasites would
cause treatment failure, but by varying the density of resistant
parasites used to seed an infection, we were able to explore the
impact of the frequency of resistant parasites at the onset of
treatment on the kinetics of treatment failure, disease severity,
transmission potential, and the detection of resistance-induced
treatment failure. We found that the rarer the resistant para-
sites when treatment began, the larger their posttreatment par-
asite relapse (Figures 1–3), likely because rarity means reduced
priming of an acquired strain-specific immune response. Con-
sequently, these infections with rare resistant parasites had
greater anemia caused by treatment failure (Figure 4). The
potential for onward transmission of resistance was least
when resistant parasites were initially rare (Figure 5).
When treatment fails and relapses occur in an endemic
setting, it can be a major challenge to determine whether the
relapse is caused by true treatment failure or by a new infection
acquired shortly after treatment. It has become a standard
practice to use molecular genotyping to distinguish reinfection
(where there will be genetically different parasites in pre- and
posttreatment samples) from recrudescence (where pre- and
posttreatment samples contain genetically identical parasites).
The use of this so-called PCR correction is limited by the
ability to detect parasite genotypes in the pretreatment sam-
ple. The standard RFLP-based assay1,7,11,12,26 can detect par-
asites clones at frequencies down to around 10%. There are
several more sensitive assays, including capillary electrophore-
sis,27 heteroduplex tracking assays,28–30 molecular barcoding
using high resolution melting assays,6,9 and ultra-deep sequenc-
ing,10,31 but for none of these methods have frequencies lower
than 1% reported.
Using any of those technologies, the PCR correction
approach would have incorrectly classified as reinfections the
treatment failures in our rare or very rare treatment groups.
This was because in those groups the resistant parasites were
well below 1% at the start of treatment. In those infections,
chemotherapy cleared parasites below microscopy (and in
some cases even below qPCR) detection levels (Figure 1),
Figure 3. Total posttreatment recrudescence density (days 10–49 postinfection) of resistant (left panels) and susceptible (right panels) asexual
parasites (top row) and gametocytes (bottom row) by percentage of resistant asexual parasites at start of treatment. Infections were initiated with
very abundant (filled squares), abundant (open squares), rare (filled circles), and very rare (open circles) resistant parasites. Dotted vertical line
indicates the detection limits of various molecular detection techniques (see introduction).
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but the resistant parasites nonetheless caused significant clini-
cal signs 7–10 days after the cessation of treatment (Figure 4E).
The concern that PCR correction will underestimate the
impact of drug resistance has been raised before.11,32 More
sensitive detection methods improve the classification of
relapses,12 but our data suggest that even with the most
advanced of the current technologies, clinically relevant treat-
ment failure due to resistance may not be identified in many
cases. Resistant parasites went undetected even by our highly
sensitive genotype-specific qPCR in several pretreatment sam-
ples (Figure 3). Despite being undetectable, those resistant
parasites relapsed to high densities and caused marked anemia.
Indeed, our results suggest the possibility that undetectably
rare resistant parasites might be the most harmful to patient
health. At least in our experiments, the most severe anemia
following treatment occurred when resistant parasites were at
frequencies of 0.01% or lower when treatment began (Figure 4).
Of course P. falciparum in people and P. chabaudi in labora-
tory mice are not the same,16,33 not least because the mice in
these experiments were naı¨ve to malaria infections, perhaps
giving the relapsing resistant clone an advantage it would not
have in a semi-immune host. Nevertheless, it is intriguing that
the relapses we saw occurred 7–10 days posttreatment, which,
scaling the 24-hour life cycle of P. chabaudi to the 48-hour life
cycle of P. falciparum, is suggestively similar to the 14–42 days
seen in relapsing P. falciparum infections.25 The precise tim-
ings will of course depend on, among other things, the intrinsic
replication rate of the parasite, host immunity, and the num-
ber of parasites surviving treatment. It might be possible to
determine whether resistance is more clinically important in
human malaria when it is rare by looking for a correlation
between time to relapse and disease severity since, all else
equal, low frequency resistance will take longer to relapse, as
it did in our experiments (Figure 4E). Yet, in high endemic
settings, the issue of distinguishing between recrudescence
and reinfection remains.
Figure 4. Top row: mean change in red blood cell (RBC) density (A) and body weight (B) through time relative to day before infection of
mice with infections initiated with very abundant susceptible parasites mixed with very abundant (blue line), abundant (red line), rare (yellow
line), and very rare (green line) resistant parasites and control mice that were sham injected with uninfected blood (grey line). Middle row:
maximum RBC loss (C) and weight loss (D) during relapse. Bottom row: time (day postinfection) until maximum RBC loss (E) and maximum
weight loss (F) during the relapse phase.
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Larger posttreatment populations of resistant parasites did
not result in more gametocytes (Figures 3, 5, and 6A). This
was partly because many gametocytes appeared soon after
treatment, so that more were produced in total when resistant
parasites were at high densities during that period (i.e., in the
very abundant and abundant experimental groups). However,
there also seem to be fewer gametocytes produced per asexual
later in the infections (Figure 3, and compare Figures 1 and 5).
This could be because of reductions in transmission stage
production by rapidly replicating parasites34 or more effective
anti-gametocyte immunity later in infections.Whatever, the net
result was that there was less potential to transmit resistance
when resistant parasites were rare at the time of treatment
than when they were more abundant.
Figure 5. Gametocyte dynamics of resistant and susceptible parasites depicted separately for each individual mouse that received an inoculum
with very abundant, abundant, rare, or very rare resistant parasites (see column headings). Vertical grey areas show timing and duration of
treatment. Asterisk indicates a mouse that received a lower dose of resistant parasites than intended, the cross indicates a mouse that died during
the infection, and the diamond indicates a mouse that did not respond to treatment because of unknown reasons. These three mice were excluded
from the analysis (see Methods and Table 1).
Figure 6. Posttreatment (day 10–49 postinfection) probability of infecting mosquitoes with resistant (A) and susceptible (B) genotypes,
estimated from an empirically derived gametocyte density—infectivity relationship (see Materials and Methods). Box plots show median, first,
and third quartile of estimations and the whiskers indicate maximum and minimum estimations or 1.5 + interquartile range out of which case
outliers are plotted. Sample sizes are as in Table 1.
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Unexpectedly, drug treatment was insufficient to fully clear
the susceptible parasites, particularly in the rare and very rare
groups (Figure 1). This relapse of the drug-sensitive clone
could be because of de novo resistance mutations, or that the
duration of treatment was not quite sufficient to eliminate all
sensitive parasites. In previous experiments, the treatment
regimen we used here was effective in clearing single-clone
susceptible infections.16 It is therefore possible that relapse of
susceptible parasites is facilitated by the presence of resistant
parasites through some unknown mechanism (e.g., drug detox-
ification). This concurrent relapse of susceptible parasites
undoubtedly affected the parasite kinetics in the rare and very
rare groups and could have partly contributed to the observed
increased anemia in these groups. Whatever the explanation,
the reemergence of sensitive parasites was less likely when
resistant parasites were at high densities after treatment
(Figure 1). We assume this is because numerically dominant
resistant parasites competitively suppress the replication of
the susceptible parasites, just as susceptible parasites sup-
pressed resistant parasites in the rare and very rare experi-
mental groups before treatment. In contrast, when both
genotypes are at similar densities, they are both able to recru-
desce (rare and very rare groups and the excluded mouse that
received less resistant parasites than intended in the abundant
group; Figures 1 and 3).
More generally, our data suggest a note of caution for
recent enthusiasms that pharmacogenetics can improve
treatment outcomes. When economically feasible, resistance
markers can be used to identify resistance before treatment
and drugs chosen accordingly (personalized medicine). This is
already the standard practice in the treatment of various bacte-
rial35,36 and HIV infections37,38 in many countries, and could
conceivably become so in malaria, at least in rich country or
military settings. We contend that a fundamental challenge
for this sort of personalized medicine will ultimately prove to
be the amount of pathogen biomass that can be sampled and
the ability of the molecular assay to detect very rare geno-
types in that sample. The problem of detecting very rare resis-
tance is the primary reason why the promise of personalized
medicine for cancer treatment39,40 is falling short of its expec-
tations.41 Malaria infections, being blood borne, are more
mixed and likely less heterogeneous than cancer tumors, but
nonetheless, the major and perhaps insurmountable challenge
will be the detection of resistance when it is extremely rare. In
our experiment, the most clinical harm was caused by para-
sites that were too rare to be detected in field samples with
current technologies.
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